- Home
- ESSA vs LYEL Comparison
ESSA vs LYEL Comparison
Compare ESSA & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESSA
- LYEL
- Stock Information
- Founded
- ESSA 1916
- LYEL 2018
- Country
- ESSA United States
- LYEL United States
- Employees
- ESSA N/A
- LYEL N/A
- Industry
- ESSA Banks
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- ESSA Finance
- LYEL Health Care
- Exchange
- ESSA Nasdaq
- LYEL Nasdaq
- Market Cap
- ESSA 195.3M
- LYEL 203.9M
- IPO Year
- ESSA N/A
- LYEL 2021
- Fundamental
- Price
- ESSA $20.64
- LYEL $0.57
- Analyst Decision
- ESSA
- LYEL Sell
- Analyst Count
- ESSA 0
- LYEL 2
- Target Price
- ESSA N/A
- LYEL $1.00
- AVG Volume (30 Days)
- ESSA 36.1K
- LYEL 1.1M
- Earning Date
- ESSA 01-27-2025
- LYEL 02-26-2025
- Dividend Yield
- ESSA 2.92%
- LYEL N/A
- EPS Growth
- ESSA N/A
- LYEL N/A
- EPS
- ESSA 1.78
- LYEL N/A
- Revenue
- ESSA $67,843,000.00
- LYEL $63,000.00
- Revenue This Year
- ESSA N/A
- LYEL N/A
- Revenue Next Year
- ESSA N/A
- LYEL N/A
- P/E Ratio
- ESSA $11.26
- LYEL N/A
- Revenue Growth
- ESSA N/A
- LYEL N/A
- 52 Week Low
- ESSA $15.29
- LYEL $0.55
- 52 Week High
- ESSA $21.50
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- ESSA 61.23
- LYEL 34.11
- Support Level
- ESSA $19.35
- LYEL $0.56
- Resistance Level
- ESSA $20.00
- LYEL $0.62
- Average True Range (ATR)
- ESSA 0.52
- LYEL 0.04
- MACD
- ESSA 0.14
- LYEL 0.01
- Stochastic Oscillator
- ESSA 100.00
- LYEL 10.41
About ESSA ESSA Bancorp Inc.
ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.